Beth Seidenberg

Beth is a longtime life sciences investor, applying her broad medical expertise to the venture capital world, where she assists entrepreneurs in translating their scientific breakthroughs into new medicines to help patients.

As a founding managing director of Westlake Village BioPartners, general partner at Kleiner Perkins, and numerous other endeavors, Seidenberg has incubated and invested in more than 40 biotech ventures since 2005. Among many others, they include ARMO Biosciences, Arresto Biosciences, Arsenal Biosciences, Atara Biotherapeutics, Cell Design Labs, Epizyme, Flexus Biosciences, iPierian, Kyverna Therapeutics, Livongo Health, Neuron23, Progyny, RAPT Therapeutics, Tesaro, Tmunity Therapeutics, and True North Therapeutics.

Beth’s impact has been recognized across the industry. She was awarded the 2022 Healthcare Businesswomen’s Association “Woman of the Year” Award and was recently named by Barron’s as one of the 100 most influential women in US finance. She was also recognized in the 2020 Forbes Midas List as a top tech investor.

In addition to her time in life science investing, Beth has significant senior-level industry experience, with leadership roles at Amgen, Bristol-Myers Squibb, and Merck Research Laboratories.

Beth holds an MD from the University of Miami Leonard M. Miller School of Medicine and a BS from Barnard College. She conducted her post-graduate training at The National Institutes of Health and Johns Hopkins University School of Medicine.